AU2003234734A8 - Peptide antagonists of tgf-beta family members and therapeutic uses thereof - Google Patents

Peptide antagonists of tgf-beta family members and therapeutic uses thereof

Info

Publication number
AU2003234734A8
AU2003234734A8 AU2003234734A AU2003234734A AU2003234734A8 AU 2003234734 A8 AU2003234734 A8 AU 2003234734A8 AU 2003234734 A AU2003234734 A AU 2003234734A AU 2003234734 A AU2003234734 A AU 2003234734A AU 2003234734 A8 AU2003234734 A8 AU 2003234734A8
Authority
AU
Australia
Prior art keywords
tgf
family members
therapeutic uses
peptide antagonists
beta family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003234734A
Other versions
AU2003234734A1 (en
Inventor
Jung San Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Original Assignee
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Louis University filed Critical St Louis University
Publication of AU2003234734A8 publication Critical patent/AU2003234734A8/en
Publication of AU2003234734A1 publication Critical patent/AU2003234734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003234734A 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof Abandoned AU2003234734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13594602A 2002-04-29 2002-04-29
US10/135,946 2002-04-29
PCT/US2003/011437 WO2003093293A2 (en) 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
AU2003234734A8 true AU2003234734A8 (en) 2003-11-17
AU2003234734A1 AU2003234734A1 (en) 2003-11-17

Family

ID=29399231

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003234734A Abandoned AU2003234734A1 (en) 2002-04-29 2003-04-15 Peptide antagonists of tgf-beta family members and therapeutic uses thereof

Country Status (4)

Country Link
EP (1) EP1534737A4 (en)
AU (1) AU2003234734A1 (en)
CA (1) CA2484994C (en)
WO (1) WO2003093293A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
AU2005311098B2 (en) * 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
KR100879239B1 (en) * 2007-04-19 2009-01-16 (주)케어젠 Peptide and Its Uses
EP2192904B1 (en) 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
EP3398966A1 (en) 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition
ES2337973B8 (en) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. ADENOVIRUS AUXILIARY SELF-INACTIVANTS FOR THE PRODUCTION OF ADENOVIRUS RECOMBINANTS OF HIGH CAPACITY.
ES2330826B1 (en) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. HIGH CAPACITY ADENOVIRUS PACKING SYSTEM.
EP2341913B1 (en) 2008-09-16 2014-11-19 Saint Louis University Method of enhancing tgf-beta signalling
JP5611322B2 (en) * 2009-04-14 2014-10-22 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Peptide having transforming growth factor activity and use thereof
CN102712933A (en) 2009-11-05 2012-10-03 西马生物医学计划公司 Regulated expression systems
WO2012001196A2 (en) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Alphaviral vectors and the uses thereof for heterologous gene expression
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
ES2523016B1 (en) 2013-05-20 2015-09-09 3P Biopharmaceuticals Alpha-viral vectors and cell lines for the production of recombinant proteins
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
WO2015101666A1 (en) 2014-01-03 2015-07-09 Fundación Biofísica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ES2146552B1 (en) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra INHIBITING PEPTIDES OF TGF / 31

Also Published As

Publication number Publication date
WO2003093293A3 (en) 2005-04-07
WO2003093293A2 (en) 2003-11-13
CA2484994C (en) 2016-06-14
EP1534737A4 (en) 2007-10-31
EP1534737A2 (en) 2005-06-01
CA2484994A1 (en) 2003-11-13
AU2003234734A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
AU2003234734A8 (en) Peptide antagonists of tgf-beta family members and therapeutic uses thereof
EP1636250A4 (en) Self-assembling peptides incorporating modifications and methods of use thereof
IL175152A0 (en) Stabilized alpha helical peptides and uses thereof
AU2003279912A8 (en) Peptide rod amphiphiles and self-assembly of same
SI1462455T1 (en) Ser-Ser-Ser-Arg peptide and medicinal uses thereof
HUP0402318A3 (en) Pharmaceutical composition comprising cyclosporin and use thereof
AU2003279841A8 (en) Uses of human zven antagonists
GB0212405D0 (en) Composition and its therapeutic use
IL177868A0 (en) Anti-inflammatory peptides and methods of use thereof
PL361364A1 (en) Peptide and pharmaceutical composition as well as their therapeutic applications
AU2003246614A8 (en) Novel use of lipopeptide preparations
GB0324457D0 (en) Modified peptides and their uses
HK1209050A1 (en) Survivin-derived peptides and use thereof
EP1357129A4 (en) Novel physiologically active peptide and use thereof
AU2003275948A8 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
AU2003256289A8 (en) Modified shine-dalgarno sequences and methods of use thereof
EP1406921A4 (en) Hypoglycaemic peptides and methods of use thereof
EP1499345A4 (en) Protein a compositions and methods of use
EP1541677A4 (en) Novel proteins and use thereof
EP1577322A4 (en) Novel proteins and use thereof
EP1699809A4 (en) Amniotic-derived peptide and uses thereof
AU2003953561A0 (en) Peptides and therapeutic uses thereof
AU2003235665A8 (en) Diagnostic and therapeutic uses of topors
EP1698696A4 (en) Target protein of antidiabetic agent and novel antidiabetic agent insuful corresponding thereto
AU2003270518A8 (en) Therapeutic anti-bgp(c-cam1) antibodies and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase